OTC · Medical - Diagnostics & Research

Pacific Edge Limited (PFGTF) Stock

$0.18 +0.00% OTC: PFGTF Healthcare

Established in 2001 and headquartered in Dunedin, New Zealand, Pacific Edge Limited is a cancer diagnostics company dedicated to inventing, developing, and commercializing diagnostic and prognostic tools. These tools are designed for the early detection and effective management of various cancers, with the company's reach extending across New Zealand, the United States, Australia, and Singapore.

Valuation

MetricValue
Price$0.18
Market Cap$223.53M
P/E Ratio-7.05
P/B Ratio25.90
P/S Ratio21.82
EPS (TTM)$-0.04
52-Week High$0.23
52-Week Low$0.07
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-190.54%
ROA-203.26%
ROCE-350.84%
Gross Margin-0.93%
Operating Margin-329.05%
Net Margin-311.14%
Debt/Equity0.12
Current Ratio2.02

Annual Financials (USD)

Metric20222023202420252026
Revenue$11.0M$20.0M$26.0M$22.0M$12.0M
Operating Profit$-22.0M$-34.0M$-46.0M$-34.0M$-38.0M
Net Profit$-20.0M$-27.0M$-30.0M$-30.0M$-36.0M
EPS$-0.03$-0.03$-0.04$-0.04$-0.04
Op Margin-193.8%-175.4%-176.2%-156.1%-329.1%

Balance Sheet (USD)

Metric20222023202420252026
Total Assets$124.0M$97.0M$65.0M$37.0M$18.0M
Total Liabilities$7.0M$9.0M$11.0M$11.0M$7.0M
Cash$105.0M$78.0M$55.0M$23.0M$8.0M
Borrowings$2.0M$1.0M$4.0M$3.0M$1.0M

Latest News

Pacific Edge Loses NZ$35m Market Value But Insiders See Windfall Of NZ$318k Simply Wall St. · May 26, 2026

Cash Flow (USD)

Metric20222023202420252026
Operating Cash Flow$-18.0M$-26.0M$-26.0M$-25.0M$-32.0M
Investing Cash Flow$-53.0M$20.0M$44.0M$5.0M$13.0M
Financing Cash Flow$-1.0M$-1.0M$-1.0M$-2.0M$-3.0M
Net Cash Flow$31.0M$-2.0M$-4.0M$-20.0M$-2.0M
Free Cash Flow$-19.0M$-28.0M$-27.0M$-26.0M$-32.0M

Valuation & Return Ratios

MetricValue
PEG Ratio1.43
EV / EBITDA-7.00
FCF Yield-12.77%
Quick Ratio1.72
Interest Coverage-497.87
Return 1Y82.56%
Return 3Y49.50%
Return 5Y—

Ownership

Insiders Held19.72%
Institutions Held34.06%
Institutions Float Held42.42%
Institutional HolderSharesReport Date
Commonwealth Intl Series TRT-Commonwealth Australia/New Zealand Fd.800,0002026-05-31
DFA INVESTMENT TRUST CO-The Asia Pacific Small Company Series279,4642026-04-30
Brighthouse Fd.s TRT II-Brighthouse/Dimensional Intl Small Company POR89,6772026-03-31
DFA INVESTMENT DIMENSIONS GROUP INC-Dimensional VA Intl Small PORT.48,9442026-04-30
Dimensional ETF Trust-Dimensional International Core Equity 2 ETF72,2612026-04-30

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
CORBFGlobal Cord Blood Corporation $0.95 -0.11% 1.56 $127.22M 0.00%
LDXHFLumos Diagnostics Holdings Ltd. $0.08 +8.70% -5.76 $57.25M 0.00%
ORXOFOrexo AB (publ) $1.55 +0.00% -1.65 $54.45M 0.00%
PBIGFParadigm Biopharmaceuticals Limited $0.12 -5.44% -1.91 $52.01M 0.00%
SHIEFShield Therapeutics plc $0.06 -10.22% -3.05 $62.03M 0.00%

About Pacific Edge Limited

Established in 2001 and headquartered in Dunedin, New Zealand, Pacific Edge Limited is a cancer diagnostics company dedicated to inventing, developing, and commercializing diagnostic and prognostic tools. These tools are designed for the early detection and effective management of various cancers, with the company's reach extending across New Zealand, the United States, Australia, and Singapore. Its operations are divided into two main segments: Commercial and Research. The company's primary offering is Cxbladder, a comprehensive series of genomic urine tests used for the identification and ongoing care of bladder cancer. Pacific Edge is actively advancing several additional products within the Cxbladder portfolio: Cxbladder Resolve, intended to identify patients likely to have aggressive or more advanced bladder cancer; Cxbladder Triage, which helps pinpoint haematuria patients with a low probability of bladder cancer; Cxbladder Detect, for the non-invasive screening of bladder and other urinary tract cancers; and Cxbladder Monitor, enabling urologists to track the recurrence of bladder cancer in patients. Beyond bladder cancer, the company is also developing Cxcolorectal, a prognostic gene signature for individuals diagnosed with stage II or stage III colorectal cancers, and has other products in its pipeline targeting bladder, gastric, colorectal, endometrial cancers, and melanoma.

Pacific Edge Limited is headquartered in NZ.

Pacific Edge Limited (PFGTF) stock trades at $0.18 with a market capitalization of $223.53M. The stock is valued at a price-to-earnings (P/E) ratio of -7.05, price-to-book of 25.90, price-to-sales of 21.82. Over the past 52 weeks the stock has ranged between $0.07 and $0.23, and currently trades 21.7% below its 52-week high.

On profitability, Pacific Edge Limited generates a return on equity (ROE) of -190.54%, return on capital employed of -350.84%, an operating margin of -329.05%, a net profit margin of -311.14%.

Official website: www.pacificedgedx.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides